PODD Stock Overview
Develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes.
| Snowflake Score | |
|---|---|
| Valuation | 4/6 |
| Future Growth | 2/6 |
| Past Performance | 5/6 |
| Financial Health | 5/6 |
| Dividends | 0/6 |
Insulet Corporation Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$193.51 |
| 52 Week High | US$223.56 |
| 52 Week Low | US$125.82 |
| Beta | 1.15 |
| 11 Month Change | -2.09% |
| 3 Month Change | 3.33% |
| 1 Year Change | -5.65% |
| 33 Year Change | -34.47% |
| 5 Year Change | 25.58% |
| Change since IPO | 1,112.47% |
Recent News & Updates
Additional Considerations Required While Assessing Insulet's (NASDAQ:PODD) Strong Earnings
Aug 16
A Look At The Intrinsic Value Of Insulet Corporation (NASDAQ:PODD)
Jul 15Recent updates
Additional Considerations Required While Assessing Insulet's (NASDAQ:PODD) Strong Earnings
Aug 16A Look At The Intrinsic Value Of Insulet Corporation (NASDAQ:PODD)
Jul 15Insulet Corporation: Insulin Pump Provider Fighting Back After Torrid 2023
Jun 11We Like These Underlying Return On Capital Trends At Insulet (NASDAQ:PODD)
May 26At US$166, Is It Time To Put Insulet Corporation (NASDAQ:PODD) On Your Watch List?
May 12Is Insulet (NASDAQ:PODD) A Risky Investment?
Apr 29Insulet Corporation's (NASDAQ:PODD) Earnings Haven't Escaped The Attention Of Investors
Apr 14Estimating The Fair Value Of Insulet Corporation (NASDAQ:PODD)
Mar 31Insulet: Insulating Patients, Investors Still Have To Wait
Mar 28Insulet (NASDAQ:PODD) Is Doing The Right Things To Multiply Its Share Price
Feb 19Is Insulet Corporation (NASDAQ:PODD) Potentially Undervalued?
Jan 22Insulet: An Interesting, Yet Expensive, Story
Jan 10Is Insulet (NASDAQ:PODD) Using Too Much Debt?
Jan 09Insulet Corporation's (NASDAQ:PODD) Earnings Haven't Escaped The Attention Of Investors
Dec 27Estimating The Intrinsic Value Of Insulet Corporation (NASDAQ:PODD)
Nov 14Insulet (NASDAQ:PODD) Shareholders Will Want The ROCE Trajectory To Continue
Oct 31We Think Insulet (NASDAQ:PODD) Is Taking Some Risk With Its Debt
Oct 01Is There Now An Opportunity In Insulet Corporation (NASDAQ:PODD)?
Sep 16Estimating The Intrinsic Value Of Insulet Corporation (NASDAQ:PODD)
Aug 14Insulet (NASDAQ:PODD) Might Have The Makings Of A Multi-Bagger
Jul 31Is Insulet (NASDAQ:PODD) Using Too Much Debt?
Jun 18Getting In Cheap On Insulet Corporation (NASDAQ:PODD) Might Be Difficult
May 22Insulet (NASDAQ:PODD) Might Have The Makings Of A Multi-Bagger
Apr 30Here's Why Insulet (NASDAQ:PODD) Has A Meaningful Debt Burden
Jan 24Insulet (NASDAQ:PODD) Shareholders Will Want The ROCE Trajectory To Continue
Dec 28Insulet: An Overpriced Play In The Medical Space
Oct 18Insulet (NASDAQ:PODD) Has A Pretty Healthy Balance Sheet
Oct 02Shareholder Returns
| PODD | US Medical Equipment | US Market | |
|---|---|---|---|
| 7D | 6.2% | 2.7% | 3.9% |
| 1Y | -5.7% | 10.5% | 25.3% |
Return vs Industry: PODD underperformed the US Medical Equipment industry which returned 9.3% over the past year.
Return vs Market: PODD underperformed the US Market which returned 24.9% over the past year.
Price Volatility
| PODD volatility | |
|---|---|
| PODD Average Weekly Movement | 5.3% |
| Medical Equipment Industry Average Movement | 8.4% |
| Market Average Movement | 6.3% |
| 10% most volatile stocks in US Market | 15.1% |
| 10% least volatile stocks in US Market | 3.2% |
Stable Share Price: PODD has not had significant price volatility in the past 3 months.
Volatility Over Time: PODD's weekly volatility (5%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2000 | 3,000 | Jim Hollingshead | www.insulet.com |
Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes. The company’s Omnipod platform includes the Omnipod 5 Automated Insulin Delivery System (Omnipod 5) which includes a proprietary AID algorithm embedded in the Pod that integrates with a third-party continuous glucose monitor to obtain glucose values through wireless bluetooth communication; Omnipod DASH that features a bluetooth enabled Pod that is controlled by a smartphone-like Personal Diabetes Manager with a color touch screen user interface; and Omnipod GO, a standalone, wearable, insulin delivery system that provides a fixed rate of continuous rapid-acting insulin for 72 hours. The company sells its products primarily through independent distributors and pharmacy channels, as well as directly in the United States, Canada, Europe, the Middle East, Australia, and internationally.
Insulet Corporation Fundamentals Summary
| PODD fundamental statistics | |
|---|---|
| Market cap | US$13.66b |
| Earnings (TTM) | US$395.30m |
| Revenue (TTM) | US$1.87b |
34.3x
P/E Ratio7.2x
P/S RatioIs PODD overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| PODD income statement (TTM) | |
|---|---|
| Revenue | US$1.87b |
| Cost of Revenue | US$592.00m |
| Gross Profit | US$1.28b |
| Other Expenses | US$885.40m |
| Earnings | US$395.30m |
Last Reported Earnings
Jun 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | 5.64 |
| Gross Margin | 68.39% |
| Net Profit Margin | 21.11% |
| Debt/Equity Ratio | 140.0% |
How did PODD perform over the long term?
See historical performance and comparison